BRPI0914024A2 - formas de dosagem farmacêutica, embalagens e uso de acetato de ciproterona - Google Patents

formas de dosagem farmacêutica, embalagens e uso de acetato de ciproterona

Info

Publication number
BRPI0914024A2
BRPI0914024A2 BRPI0914024A BRPI0914024A BRPI0914024A2 BR PI0914024 A2 BRPI0914024 A2 BR PI0914024A2 BR PI0914024 A BRPI0914024 A BR PI0914024A BR PI0914024 A BRPI0914024 A BR PI0914024A BR PI0914024 A2 BRPI0914024 A2 BR PI0914024A2
Authority
BR
Brazil
Prior art keywords
packaging
dosage forms
pharmaceutical dosage
cyproterone acetate
cyproterone
Prior art date
Application number
BRPI0914024A
Other languages
English (en)
Portuguese (pt)
Inventor
Carole S Ben-Maimon
Howard Hait
Kathleen Reape
Salah U Ahmed
Sundeep Sethia
Original Assignee
Teva Womens Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Womens Health Inc filed Critical Teva Womens Health Inc
Publication of BRPI0914024A2 publication Critical patent/BRPI0914024A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
BRPI0914024A 2008-10-10 2009-10-12 formas de dosagem farmacêutica, embalagens e uso de acetato de ciproterona BRPI0914024A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13689308P 2008-10-10 2008-10-10
PCT/US2009/060381 WO2010042930A1 (en) 2008-10-10 2009-10-12 Methods for treating vasomotor symptoms in castrated prostatic cancer patients with low dose cyproterone acetate

Publications (1)

Publication Number Publication Date
BRPI0914024A2 true BRPI0914024A2 (pt) 2015-11-03

Family

ID=42101000

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914024A BRPI0914024A2 (pt) 2008-10-10 2009-10-12 formas de dosagem farmacêutica, embalagens e uso de acetato de ciproterona

Country Status (9)

Country Link
US (1) US8288342B2 (enExample)
EP (1) EP2381946A4 (enExample)
JP (1) JP2012505253A (enExample)
AU (1) AU2009303272A1 (enExample)
BR (1) BRPI0914024A2 (enExample)
CA (1) CA2739887A1 (enExample)
EA (1) EA022208B1 (enExample)
MX (1) MX2011003726A (enExample)
WO (1) WO2010042930A1 (enExample)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2345377A1 (de) 1973-09-06 1975-03-20 Schering Ag Pharmazeutische zubereitung i
DE2817157A1 (de) * 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie
DE3331824A1 (de) * 1983-09-01 1985-03-21 Schering AG, Berlin und Bergkamen, 1000 Berlin Verfahren zur herstellung von 17(alpha)-acyloxy-6-chlor-1(alpha),2(alpha)-methylen-3,20-dionen
DE3333240A1 (de) * 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen Mittel zur transdermalen applikation von arzneimittelwirkstoffen
US4498420A (en) * 1984-01-23 1985-02-12 Container Corporation Of America Carton for insects
DE3934656A1 (de) * 1989-10-13 1991-04-18 Schering Ag Verfahren zur herstellung von waessrigen dispersionen
DE3936328A1 (de) * 1989-10-27 1991-05-02 Schering Ag Pharmazeutische praeparate
IE67345B1 (en) * 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
US5498420A (en) * 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
BE1007402A5 (nl) * 1993-03-26 1995-06-06 Adir Nasale farmaceutische preparaten met progestagene stof.
US6165504A (en) * 1998-09-23 2000-12-26 Barr Laboratories, Inc. Methods for treating hot flashes and improving the quality of life of castrated prostatic cancer patients
US6613758B1 (en) * 1999-04-02 2003-09-02 Barr Laboratories, Inc. Method for treating osteoporosis in castrated prostatic cancer patients
FR2821555B1 (fr) * 2001-03-01 2003-05-16 Besins Int Lab Progestatif co-micronise avec un tensioactif, composition pharmaceutique le comprenant, leurs procedes de fabrication et leurs utilisations
US20040024230A1 (en) * 2002-04-29 2004-02-05 Boehringer Ingelheim International Gmbh Synthesis of cyproterone acetate
US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US7371405B2 (en) * 2003-12-22 2008-05-13 Mcneil-Ppc, Inc. Consumer customized dosage forms
MY142989A (en) * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs

Also Published As

Publication number Publication date
WO2010042930A1 (en) 2010-04-15
EA201170414A1 (ru) 2011-10-31
EP2381946A1 (en) 2011-11-02
US20100260860A1 (en) 2010-10-14
CA2739887A1 (en) 2010-04-15
EP2381946A4 (en) 2012-08-08
US8288342B2 (en) 2012-10-16
MX2011003726A (es) 2011-08-17
JP2012505253A (ja) 2012-03-01
AU2009303272A1 (en) 2010-04-15
EA022208B1 (ru) 2015-11-30

Similar Documents

Publication Publication Date Title
IL209499A (en) Human monoclonal antibody against influenza virus a, Pharmaceutical preparations containing it and its use in drug preparation
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0917315A2 (pt) anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
HUE053357T2 (hu) Gyógyszerészeti készítmény és annak beadásai
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI1016219A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI1008793A2 (pt) composto, uso de um composto, e, composição farmacêutica
BR112013008259A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112012002331A2 (pt) composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica
BRPI1007018A2 (pt) composto, composição farmacêutica, e , uso de um composto.
BR112012013148A2 (pt) formulação farmacêutica e uso
BR112013015397A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112013016772A2 (pt) composto, uso do composto, composição farmacêutica, oligonucleotídeo e conjugado
BRPI1008906A2 (pt) composto, composição farmacêutica, e, uso de um composto.
BR112013011448A2 (pt) composto, composição farnmacêutica, e, uso do composto
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0913822A2 (pt) forma farmacêutica oral e uso da forma farmacêutica
BRPI0810161A2 (pt) Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
BRPI0921879A2 (pt) composto, composição farmacêutica , e, uso de um composto
BRPI0921699A2 (pt) complexo antioxidante, composicoes cosmeticas e farmaceutica contendo o referido complexo e uso deste complexo
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
BRPI0917661A2 (pt) produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]